Levothyroxine treatment improved clinical outcomes of patients with heart failure and Subclinical hypothyroidism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076613

Enrollment

Unknown

Registered

2023-10-13

Start date

2023-10-15

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

levothyroxine group: levothyroxine 12.5ug/day

control group:routine therapy

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. aged 30–80 years; 2. Patients who were diagnosed with heart failure based on the American College of Cardiology/American Heart Association guidelines ; 3. New York Heart Association (NYHA) class II–IV; 4. Patients With TSH >4.5mIU/L and normal FT4.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Patients with acute decompensation heart failure. 2. Patients receiving levothyroxine therapy in the past three months. 4. Patients with cancer. 5. Patients with overt hypothyroidism or low T3 syndrome.

Design outcomes

Primary

Measure	Time frame
FMD;	—

Secondary

Measure	Time frame
Major adverse cardiovascular event (MACE)-free survival;LVEF improvement;	—

Countries

China

Contacts

Public ContactTan Qiang

The first hospital of Qinhuangdao

qhdtanqiang@aliyun.com+86 335 590 8658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026